Cargando…

Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with poor clinical outcomes. Dysregulated MYC expression, which is associated with protein arginine methyltransferase 5 (PRMT5) dependency, is a recurrent feature of BPDCN. Although recent studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rethnam, Malini, Tan, Darren Qiancheng, Tan, Shi Hao, Li, Jia, Yokomori, Rui, Li, Ying, Yang, Henry, Sanda, Takaomi, Suda, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631685/ https://www.ncbi.nlm.nih.gov/pubmed/35482445 http://dx.doi.org/10.1182/bloodadvances.2021006306

Ejemplares similares

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

PD-1 inhibition in advanced myeloproliferative neoplasms
por: Hobbs, Gabriela, et al.
Publicado: (2021)

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
por: Pecquet, Christian, et al.
Publicado: (2023)

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
por: Gorak, Edward J., et al.
Publicado: (2023)

Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity
por: Molteni, Elisabetta, et al.
Publicado: (2023)

Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study
por: Tuyet Kristensen, Daniel, et al.
Publicado: (2023)

Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens
por: Seetharam, Sumanth Mosale, et al.
Publicado: (2023)

Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
por: Chovanec, Jack, et al.
Publicado: (2022)

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
por: Nannya, Yasuhito, et al.
Publicado: (2023)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms
por: Loh, Kah Poh, et al.
Publicado: (2022)

Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
por: Levy, Brynn, et al.
Publicado: (2022)

Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells
por: Tan, Ge, et al.
Publicado: (2022)

Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia
por: Song, Huan, et al.
Publicado: (2022)

Blastic plasmacytoid dendritic cell neoplasm
por: Lencastre, André, et al.
Publicado: (2013)

Blastic plasmacytoid dendritic cell neoplasm
por: Rai, Manoj Ponadka, et al.
Publicado: (2018)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

Blastic Plasmacytoid Dendritic Cell Neoplasm on the Scalp
por: Fukushi, Sawako, et al.
Publicado: (2011)

Blastic plasmacytoid dendritic cell neoplasm in the CSF
por: Jeong, Huijeong, et al.
Publicado: (2017)

Juvenile Blastic Plasmacytoid Dendritic Cell Neoplasm
por: HAYANI, Kinan M., et al.
Publicado: (2020)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2021)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n6hk2bfv0f45kqsm1h7u4h5iad